Venkata Vamsi Krishna Venuganti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Venkata Vamsi Krishna Venuganti has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Shubhmita Bhatnagar
Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Hyderabad, Telangana, 500078, India
12 shared publications Suman Labala
Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana, 500078, India
10 shared publicationsAnup Jose
A Department of Pharmacy , Birla Institute of Technology and Science (BITS) Pilani , Hyderabad Campus , Hyderabad , India
7 shared publicationsPraveen Kumar Mandapalli
Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Hyderabad, 500078, Telangana, India
7 shared publicationsGirdhari Roy
Department of Pharmacy, Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Hyderabad, India
6 shared publicationsLeela Sai Lokesh Janardhanam
Birla Institute of Technology and Science (BITS) Pilani, Hyderabad, India
6 shared publications
Latest Publications
- 7 August 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43  (9)
Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy
- 7 August 2026
- Published by Springer Nature in Medical Oncology
- Vol. 43  (9)
Survivin mRNA lipid nanoparticles and CTLA-4 inhibitor co-delivery activates anti-tumor cytotoxic T-lymphocytes for oral cancer immunotherapy
- Open Access
- 11 May 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6  (7) , 101226
Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma
- 11 May 2026
- Published by Elsevier in Ophthalmology Science
- Vol. 6  (7) , 101226
Open AccessTopotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma
- 16 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126869
Dual drug loaded dissolvable annular microneedle patch to treat bacterial conjunctivitis
- 16 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126869
Dual drug loaded dissolvable annular microneedle patch to treat bacterial conjunctivitis
- 1 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126834
Evaluation of 3D bioprinted pancreatic islets for insulin secretion in diabetic rats
- 1 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 696, 126834
Evaluation of 3D bioprinted pancreatic islets for insulin secretion in diabetic rats
- 6 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126570
3D printed mucoadhesive gastric patch provides long-acting naltrexone delivery
- 6 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126570
3D printed mucoadhesive gastric patch provides long-acting naltrexone delivery
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Nanoscience
- Vol. 21  (6) , 983-1007
Transforming Biologics Delivery through Microneedles
This review explores the potential of microneedles (MNs) in enhancing the delivery of biologics vital for treating conditions, including infectious diseases, cancer, and autoimmune disorders. The COVID-19 pandemic has amplified the demand for biologics, prompting research and development. The global biologics market is expected to grow substantially due to the rise of personalized medicine. Large, complex molecules, including proteins, peptides, and vaccines, are known as biologics, and a potential technique for their delivery is microneedles. MNs come in various forms: solid, hollow, coated, dissolvable, and hydrogel MNs. Traditional drug delivery methods have limitations, while transdermal drug delivery via Microneedles offers a promising alternative. Microneedles painlessly penetrate the skin's barrier, forming temporary microchannels for effective medication administration. This minimally invasive, self-administered technique increases patient comfort and compliance and eliminates the complications of oral medications and injections, indicating a bright future for biologic drug administration. Microneedles hold the promise to reshape healthcare delivery by facilitating broader access to vaccines, insulin, and other crucial biologics.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Nanoscience
- Vol. 21  (6) , 983-1007
Transforming Biologics Delivery through Microneedles
This review explores the potential of microneedles (MNs) in enhancing the delivery of biologics vital for treating conditions, including infectious diseases, cancer, and autoimmune disorders. The COVID-19 pandemic has amplified the demand for biologics, prompting research and development. The global biologics market is expected to grow substantially due to the rise of personalized medicine. Large, complex molecules, including proteins, peptides, and vaccines, are known as biologics, and a potential technique for their delivery is microneedles. MNs come in various forms: solid, hollow, coated, dissolvable, and hydrogel MNs. Traditional drug delivery methods have limitations, while transdermal drug delivery via Microneedles offers a promising alternative. Microneedles painlessly penetrate the skin's barrier, forming temporary microchannels for effective medication administration. This minimally invasive, self-administered technique increases patient comfort and compliance and eliminates the complications of oral medications and injections, indicating a bright future for biologic drug administration. Microneedles hold the promise to reshape healthcare delivery by facilitating broader access to vaccines, insulin, and other crucial biologics.
- 14 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125863
Localized delivery of Aza-BODIPY photosensitizer using dissolvable microneedle patch to treat oral carcinoma
- 14 June 2025
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 681, 125863
Localized delivery of Aza-BODIPY photosensitizer using dissolvable microneedle patch to treat oral carcinoma
- 16 May 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26  (5) , 1-18
Fabrication of 3D Printed Microneedle Patch for the Simultaneous Delivery and Detection of Melatonin from Interstitial Fluid
Interstitial fluid (ISF) offers a potential alternative to invasive blood sample collection for biomolecule analysis. Microneedle (MN) patch application ca
- 16 May 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26  (5) , 1-18
Fabrication of 3D Printed Microneedle Patch for the Simultaneous Delivery and Detection of Melatonin from Interstitial Fluid
Interstitial fluid (ISF) offers a potential alternative to invasive blood sample collection for biomolecule analysis. Microneedle (MN) patch application ca
- Open Access
- 16 May 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22  (6) , 3331-3350
Influence of Choline-Based Ionogel on Transdermal Delivery of Vancomycin Hydrochloride
Ionic liquids (ILs) have attracted considerable interest as new drug delivery solvents because of their superior transdermal absorption of large molecular weight drugs across the biological barrier and their capacity to solubilize hydrophobic compounds. It is difficult to administer hydrophilic peptide treatments with large molecular weights through the skin. Vancomycin hydrochloride (VH) is a glycopeptide antibiotic that cures bacterial infections. With a molecular weight of 1449 Da and a high water solubility of 50 mg/mL, VH is an impressive compound. This study aimed to quantify the amount of VH transdermal penetration by analyzing the influence of choline-based ILs. Choline geranate was used as an IL in this investigation, whereas oleic acid (OA) (unsaturated) and palmitic acid (PA) (saturated) were chosen as the two types of fatty acids. The molar ratio of choline bicarbonate (CB) to either OA (CO) or PA (CP) was 2:1. In an additional series of trials, choline geranate (CAGE) ILs were prepared by mixing CB and geranic acid in a 1:2 molar ratio. For NMR spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and Fourier transform infrared investigations, these formulations were characterized. Zeta potential indicated that all of the formulations had negative charges. The decreased irritation potential of CAGE, as shown by conductivity studies, makes it appropriate for skin application. To determine which formulation enhancers worked best, ex vivo skin permeation studies were carried out on both intact and tape-stripped skin. After 48 h, skin transport investigations showed that neat VH did not penetrate the excised porcine skin. Nevertheless, the CO and CP-based formulations greatly improved the skin penetration (6729 ± 437 μg/cm2) and retention (3892 ± 215 μg/g) of VH across the tape-stripped skin, whereas CAGE exhibited the most significant improvement (p < 0.05). Ionogel (CAGE-P) was finally fabricated by combining CAGE with 22.7% w/v Pluronic F-127 and 45.0% w/v PEG-400. The physical and rheological properties of VH-loaded CAGE-P gel were examined. The amount of VH permeated across the CAGE-P gel cotreated intact skin was 369 ± 41 μg/cm2, but that penetrated tape-stripped skin was 7543 ± 585 μg/cm2. The skin's barrier property underwent notable modifications (p < 0.05) following incubation with CAGE and CAGE-P gel formulations, as seen in the biophysical investigations conducted at various time intervals. Taken together, CAGE-Pluronic F-127 ionogel is promising and efficient as a topical formulation for the administration of VH in a localized and systemic manner.
- 16 May 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22  (6) , 3331-3350
Open AccessInfluence of Choline-Based Ionogel on Transdermal Delivery of Vancomycin Hydrochloride
Ionic liquids (ILs) have attracted considerable interest as new drug delivery solvents because of their superior transdermal absorption of large molecular weight drugs across the biological barrier and their capacity to solubilize hydrophobic compounds. It is difficult to administer hydrophilic peptide treatments with large molecular weights through the skin. Vancomycin hydrochloride (VH) is a glycopeptide antibiotic that cures bacterial infections. With a molecular weight of 1449 Da and a high water solubility of 50 mg/mL, VH is an impressive compound. This study aimed to quantify the amount of VH transdermal penetration by analyzing the influence of choline-based ILs. Choline geranate was used as an IL in this investigation, whereas oleic acid (OA) (unsaturated) and palmitic acid (PA) (saturated) were chosen as the two types of fatty acids. The molar ratio of choline bicarbonate (CB) to either OA (CO) or PA (CP) was 2:1. In an additional series of trials, choline geranate (CAGE) ILs were prepared by mixing CB and geranic acid in a 1:2 molar ratio. For NMR spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and Fourier transform infrared investigations, these formulations were characterized. Zeta potential indicated that all of the formulations had negative charges. The decreased irritation potential of CAGE, as shown by conductivity studies, makes it appropriate for skin application. To determine which formulation enhancers worked best, ex vivo skin permeation studies were carried out on both intact and tape-stripped skin. After 48 h, skin transport investigations showed that neat VH did not penetrate the excised porcine skin. Nevertheless, the CO and CP-based formulations greatly improved the skin penetration (6729 ± 437 μg/cm2) and retention (3892 ± 215 μg/g) of VH across the tape-stripped skin, whereas CAGE exhibited the most significant improvement (p < 0.05). Ionogel (CAGE-P) was finally fabricated by combining CAGE with 22.7% w/v Pluronic F-127 and 45.0% w/v PEG-400. The physical and rheological properties of VH-loaded CAGE-P gel were examined. The amount of VH permeated across the CAGE-P gel cotreated intact skin was 369 ± 41 μg/cm2, but that penetrated tape-stripped skin was 7543 ± 585 μg/cm2. The skin's barrier property underwent notable modifications (p < 0.05) following incubation with CAGE and CAGE-P gel formulations, as seen in the biophysical investigations conducted at various time intervals. Taken together, CAGE-Pluronic F-127 ionogel is promising and efficient as a topical formulation for the administration of VH in a localized and systemic manner.